Scientifically trained experts focused on human-centric impact

Specialist market access professional who is highly skilled in cost-effectiveness analyses, PBS pricing negotiations, financial analyses and revenue calculators

Roxanne has experience in health outcomes research and PBS reimbursement.

Kate joined HTANALYSTS as a consultant in 2022, she has experience in reimbursement submissions, feasibility studies and the design and implementation of strategies for conducting systematic reviews.

Drawing on over a decade of experience in pharmaceuticals and consulting, Lucy specialises in market access, value communication, and evidence-based strategy, with expertise in PBAC and Pharmac submissions, pricing strategy, and social return on investment analysis.”

Ee Lin joined HTANALYSTS as a Consultant in 2023 and has over 15 years’ experience in the pharmaceutical industry and a background in clinical pharmacy.

Combining expertise in health economics, economic modelling, and market access strategy, Daniël specialises in reimbursement submissions, impact analyses, and regulatory evaluations to support the adoption of pharmaceuticals and medical technologies.

With a background in infectious disease surveillance and epidemiology, Eleanor applies her expertise in public health and health economics to support equitable healthcare access and policy development.

With 5 years’ experience managing New Zealand’s national pharmaceutical budget, Alexandria uses her strategic experience in public procurement and portfolio optimisation to provide strategic market access recommendations, driving improved outcomes for patients and clients.

With a background in engineering research, Ingrid brings expertise in biomedical engineering, nanoparticle technology, and scientific writing to support healthcare innovation and analysis.

Specialising in economic modelling and health economics, Eden applies his expertise in economics, public policy, and cost-benefit analysis to deliver strategic insights and actionable solutions for clients.

With a background in academia and consulting, Amy has experience in health technology assessment submissions across PBAC, MSAC, and PHARMAC, as well as in feasibility assessments, evidence generation, and global value and reimbursement strategy projects across a broad range of therapeutic areas.

With a background in pharmacy, health policy, and strategy consulting, Gail brings expertise in PBAC and MSAC reimbursement submissions, market access strategy, and economic evaluation to support the value of new therapies.

With a background in medical science research and business management consulting, Annmarie holds a Bachelor of Science from the University of Sydney and a Master of Science in Biomedical Engineering from UTS.

An Accredited Practising Dietitian, Adele brings experience in clinical and policy research, supported by a Bachelor of Science and a Master of Nutrition and Dietetics from the University of Sydney.

Nicole Ong is a Consultant at HTANALYSTS. She has contributed to a range of health technology assessment including PBAC and MSAC submissions, feasibility assessments across multiple clinical indications, and broader value work such as impact assessments and social return on investments.

Holly is a Consultant at HTANALYSTS with a background in economics and health & social care policy.

Hugh Smith is a Consultant at HTANALYSTS. He contributes to projects in health economic modelling and market access, supporting health technology assessment submissions and related strategic initiatives.

Experienced Senior project / program manager professional with 20 years experience in delivery, innovation and results orientated project management.

Erica Doutty joined HTANALYSTS in June 2025 and is currently building out a centre of excellence for Patient Engagement. She brings over 20 years of experience in media, communications, product marketing and program management.

Erin is a Learning & Development leader with extensive experience creating practical, business-focused learning solutions across large and complex organisations in both the private and public sectors, including health and regulated environments.